{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:30:48Z","timestamp":1789597848826,"version":"build-2803163510"},"posted":{"date-parts":[[2026,1,24]]},"group-title":"Health Policy","reference-count":26,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the potential effect of implementing population-based prostate-specific antigen (PSA) screening in England on overdiagnosis and testing rates compared with the current opportunistic testing policy.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Statistical modeling study. English data on rates of prostate cancer by stage, PSA testing, and life expectancy were merged with epidemiological data on lead time to evaluate plausible overdiagnosis and PSA testing rates from an organized population-based program, in comparison with the current opportunistic policy. In the base-case scenario, organized screening increased the rate of PSA testing in men aged 50 \u2013 69 year and decreased PSA testing in older men. An alternative modeling approach estimated change in overdiagnosis using data from the UK \u201cCAP\u201d trial.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>England, 2018\/19.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Adult men.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Rates of PSA testing, early-stage prostate cancer incidence, and overdiagnosis (prostate cancer that would not be diagnosed in a man\u2019s lifetime but for the PSA test).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the base scenario, introduction of population-based screening led to an approximate 25% reduction in both PSA testing and overdiagnosis rates in the target population compared with the current policy. This was due to the anticipated decrease in PSA testing and overdiagnosis in men aged 70+ years being larger than the projected increase in PSA testing and overdiagnosis in men 50-69 years. The overall incidence of early-stage cancer prostate cancer was similar. Population-based screening was found to detect more early-stage cancers that were not overdiagnosed, and is therefore likely to have a greater impact on prostate-cancer morbidity and mortality than current policy. Findings were robust in sensitivity analyses including the entirely independent modeling approach based on CAP.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Opportunistic screening policies in England have led to high rates of overdiagnosis and PSA testing. In comparison with current policy, a risk-adapted, population-based prostate cancer screening program would likely reduce the number of PSA tests and overdiagnoses, and increase benefits of PSA testing from reduced prostate-cancer mortality Population health in England would be improved by either adopting an organized program or by ending PSA testing in primary care.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Research in context<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Evidence before this study<\/jats:title>\n                    <jats:p>It is known that screening for prostate cancer using the PSA test results in considerable overdiagnosis. As a result of these concerns, UK national policy, like most high-income countries, is to have no population-based screening program but to allow men to obtain a PSA test after shared decision-making with a primary care physician. This has led to very high rates of PSA testing among men aged over 70, who experience limited benefit from screening but who are at high risk of overdiagnosis. A small number of studies have modeled the impact of implementing population-based PSA screening but have not incorporated how such a program would affect opportunistic screening in older men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Added value of this study<\/jats:title>\n                    <jats:p>Data on rates of prostate cancer by stage, PSA testing and life expectancy in England were merged with epidemiological data on lead time to model statistical rates of overdiagnosis and PSA testing from an organized population-based program in comparison to current policy. Changes in PSA testing in men above screening age were based on how empirical data on how rates changed in the one country that has implemented population-based screening, Lithuania. We estimate that introduction of population-based screening would reduce both PSA testing and overdiagnosis by about 25%. This is due to the anticipated decrease in PSA testing and overdiagnosis in men aged 70+ years being larger than the projected increase in PSA testing and overdiagnosis in men 50-69 years subject to the population-based screening program. Population-based screening was found to detect more early-stage cancers that were not overdiagnosed and is therefore likely to have a greater impact on prostate-cancer morbidity and mortality than current policy. Findings were robust in sensitivity analyses including an entirely independent modeling approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications of all the available evidence<\/jats:title>\n                    <jats:p>Opportunistic screening policies in England have led to high rates of overdiagnosis and PSA testing. In comparison with current policy, a risk-adapted, population-based prostate cancer screening program would likely reduce the number of PSA tests and overdiagnoses, and increase benefits of PSA testing from reduced prostate-cancer mortality Population health in England would be improved by either adopting an organized PSA screening program or by ending PSA testing in primary care<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.64898\/2026.01.23.26344710","type":"posted-content","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T20:55:13Z","timestamp":1769460913000},"source":"Crossref","is-referenced-by-count":1,"title":["Effect of implementing population-based prostate-specific antigen screening on testing rates and prostate cancer overdiagnosis in England: a statistical modelling study"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-6503","authenticated-orcid":false,"given":"Andrew J.","family":"Vickers","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6327-4357","authenticated-orcid":false,"given":"Adam","family":"Brentnall","sequence":"additional","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026042701200867000_2026.01.23.26344710v3.1","unstructured":"UK National Screening Committee, Prostate Cancer. https:\/\/view-health-screening-recommendations.service.gov.uk\/prostate-cancer\/. Accessed November 19 2025."},{"key":"2026042701200867000_2026.01.23.26344710v3.2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpo.2024.0040"},{"key":"2026042701200867000_2026.01.23.26344710v3.3","unstructured":"Guidance. PSA testing: advice for men without symptoms https:\/\/www.gov.uk\/government\/publications\/prostate-specific-antigen-testing-description-in-brief. Accessed November 19 2025."},{"key":"2026042701200867000_2026.01.23.26344710v3.4","unstructured":"PSA Test. UK NHS. https:\/\/www.nhs.uk\/tests-and-treatments\/psa-test\/. Accessed November 19 2025."},{"key":"2026042701200867000_2026.01.23.26344710v3.5","unstructured":"National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. https:\/\/www.nice.org.uk\/guidance\/ng12\/resources\/suspected-cancer-recognition-and-referral-pdf-1837268071621. Accessed November 19 2025."},{"key":"2026042701200867000_2026.01.23.26344710v3.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083800"},{"key":"2026042701200867000_2026.01.23.26344710v3.7","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-26"},{"key":"2026042701200867000_2026.01.23.26344710v3.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071082"},{"key":"2026042701200867000_2026.01.23.26344710v3.9","unstructured":"NHS England Screening. https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/screening\/. Accessed November 19 2025."},{"key":"2026042701200867000_2026.01.23.26344710v3.10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123826"},{"key":"2026042701200867000_2026.01.23.26344710v3.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.06.006"},{"key":"2026042701200867000_2026.01.23.26344710v3.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4011"},{"key":"2026042701200867000_2026.01.23.26344710v3.13","unstructured":"Science Media Centre. expert reaction to 23 year follow up data from The European Randomized Study of Screening for Prostate Cancer. October 29 2025. https:\/\/www.sciencemediacentre.org\/expert-reaction-to-23-year-follow-up-data-from-the-european-randomized-study-of-screening-for-prostate-cancer. Accessed November 19 2025. ."},{"key":"2026042701200867000_2026.01.23.26344710v3.14","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1509"},{"key":"2026042701200867000_2026.01.23.26344710v3.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000643"},{"key":"2026042701200867000_2026.01.23.26344710v3.16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp001"},{"key":"2026042701200867000_2026.01.23.26344710v3.17","unstructured":"Prostate Cancer Research. Prostate Cancer Screening: The Impact on the NHS. https:\/\/www.prostate-cancer-research.org.uk\/wp-content\/uploads\/2025\/10\/Prostate-Cancer-Screening-The-Impact-on-the-NHS-Report.pdf. Accessed November 19 2025. ."},{"key":"2026042701200867000_2026.01.23.26344710v3.18","unstructured":"University of Sheffield School of Medicine and Population Health (SCHARR). Cost-effectiveness of Prostate Cancer Screening for Men of Average and High Risk. University of Sheffeld 2025."},{"key":"2026042701200867000_2026.01.23.26344710v3.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2509793"},{"key":"2026042701200867000_2026.01.23.26344710v3.20","unstructured":"Rapid Cancer Registration Data: Incidence and treatment dashboard. NHS England. https:\/\/nhsd-ndrs.shinyapps.io\/rcrd\/. Accessed November 19 2025. ."},{"key":"2026042701200867000_2026.01.23.26344710v3.21","unstructured":"National life tables: UK. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables. Accessed November 19 2025. ."},{"key":"2026042701200867000_2026.01.23.26344710v3.22","unstructured":"UK Oiice of National Statistics. https:\/\/population-by-ethnicity\/demographics\/age-groups\/latest\/]. Accessed November 19 2025. ."},{"key":"2026042701200867000_2026.01.23.26344710v3.23","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2024.0376"},{"key":"2026042701200867000_2026.01.23.26344710v3.24","unstructured":"NHS England Statistics. https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/screening\/]. Accessed November 19 2025. ."},{"key":"2026042701200867000_2026.01.23.26344710v3.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5750"},{"key":"2026042701200867000_2026.01.23.26344710v3.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.009"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.01.23.26344710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:20:25Z","timestamp":1777278025000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.01.23.26344710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":26,"URL":"https:\/\/doi.org\/10.64898\/2026.01.23.26344710","relation":{},"subject":[],"published":{"date-parts":[[2026,1,24]]},"subtype":"preprint"}}